“The first set of results from our Phase 3 Covid-19 vaccine trial provides the initial evidence of our vaccine’s ability to prevent Covid-19,” Pfizer chairman and CEO Albert Bourla said in a statement.
“We are a significant step closer to providing people around the world with a much-needed breakthrough to help bring an end to this global health crisis,” he said.
Pfizer and German partner BioNTech SE are the first drugmakers to release successful data from a large-scale clinical trial of a coronavirus vaccine. The companies said they have so far found no serious safety concerns and expect to seek US authorization this month for emergency use of the vaccine.
Health experts said Pfizer’s results were positive for all COVID-19 vaccines currently in development since they show the shots are going after the right target and are a proof of concept that the disease can be halted with vaccination.
Which countries will get Pfizer covid vaccine first?
- Regulators on both sides of the Atlantic ocean are working to speed a review of the shot’s safety and effectiveness after the data showed it prevented more than 90% of infections
- Pfizer and BioNTech expect to ramp up production of their Covid vaccine significantly next year, with capacity for as many as 1.3 bn doses